LOGO
LOGO

Clinical Trial Calendar

Company Name Coherus Oncology, Inc.
Event Name Initial data from Phase 1b dose optimization study of CHS-114 in combination with toripalimab
Indication Second-line head and neck squamous cell carcinoma (HNSCC)
Outcome Date
Outcome
Result Date Q2 2026